Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03166098 · ClinicalTrials.gov registry record
The Role of Dysmyelination in Cognitive Impairment of Psychotic Spectrum Disorders
A clinical trial of Schizophrenia and Bipolar Disorder, sponsored by NYU Langone Health.
- Completed
- Registry status
- 139
- Enrollment target
- 1
- Study location
NCT03166098 is a study of Schizophrenia and Bipolar Disorder that has completed, run by NYU Langone Health. The registered enrollment target is 139 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03166098, a study of Schizophrenia and Bipolar Disorder, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 139 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single center study that uses both between-group comparisons and correlational analyses to establish biomarkers of dysmyelination and cognitive impairment in Psychotic Spectrum Disorders using imaging and neuropsychological assays.The study will provide non-invasive biomarkers of cognitive dysfunction in Psychotic Spectrum Disorder.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Cognitive Function Assessments
Study Locations (1)
New York
- New York University School of Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2016-07-05 |
| Est. Completion | 2022-03-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03166098
The ClinicalTrials.gov registry entry for NCT03166098 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 139 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (37% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which Cognitive Function Assessments is the first listed.
NCT03166098 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03166098 about?
NCT03166098 is a clinical study titled "The Role of Dysmyelination in Cognitive Impairment of Psychotic Spectrum Disorders". This is a single center study that uses both between-group comparisons and correlational analyses to establish biomarkers of dysmyelination and cognitive impairment in Psychotic Spectrum Disorders using imaging and neuropsychological assays.The study will provide non-invasive biomarkers of cognitive...
What is the current status of trial NCT03166098?
This trial is currently completed. The enrollment target is 139 participants. The study started on 2016-07-05. Estimated completion is 2022-03-01.
What conditions does trial NCT03166098 study?
This clinical trial studies the following conditions: Schizophrenia, Bipolar Disorder.
What interventions are being tested in trial NCT03166098?
The interventions under investigation include: Cognitive Function Assessments (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03166098?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03166098 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Taking Action for College Students
RECRUITING · NA
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.